Only those thrombus samples from both IST and CT groups with a) enough material to perform the analyses, b) homogeneous macroscopic appearance and c) similar total weights, were used in the study in order to reduce sample variability. The background and clinical description of STEMI-patients included in the study is provided in Table 1. 
Pharmacologic treatment before PCI included aspirin in loading doses of 300 mg and, either 600 mg of clopidogrel in patients admitted before 2011, or 60 mg of prasugrel in those admitted from 2011 onwards, plus 5,000-10,000 IU of unfractionated heparin.
Glycoprotein IIb/IIIa inhibitor (eptifibatide), was used in 37 patients, with a double bolus of 180 g/kg i.v. (with a time lapse of 10 minutes during the procedure) followed by a 2 μg/kg/min infusion for 12 h.
Among the 21 IST patients included in the study, the reasons for the prior stent implantation were: STEMI (13 patients), unstable angina (UA; 2 patients), positive ischemia detection test (2 patients) , and dilated ischemic cardiomyopathy (1 patient). The reason for stent implantation was unknown in 3 patients. The pre-implanted stent was baremetal (BMS) in 38% of cases, drug-eluting stent (DES) in 33% and unknown in 29%. Most IST patients suffered a late or a very-late thrombosis (76%). Within the CT group, 42% had suffered a previous ischemic event whereas 58% had not. The mean onset-of-pain-to-PCI time for the 45 patients was 273 ( 25) minutes.
The study consisted of three phases: I) in the first phase the cellular composition of both types of thrombus samples was analyzed by immunohistochemistry (N=7/group; baseline characteristics of both groups of patients are outlined in Suppl. Table 1 ); II) in the second phase of the study the protein composition of IST samples (N=9) was compared to that of CT (N=10; baseline characteristics of both groups of patients are outlined in Suppl. Table   2 ) by differential proteomic studies; and III) in the third phase the potential impact of thrombus protein changes on serum levels of differential proteins was analyzed by ELISA in 14 patients with IST (including 4 patients analyzed in phase I and 5 patients analyzed in phase II) and 18 patients with CT (including 8 patients analyzed in phase I and 3 patients analyzed in phase II; baseline characteristics of both groups of patients are outlined in Suppl. Table 3) . A schematic view of the workflow of the study is shown in Supplemental The Institutional review board of the Puerta de Hierro Hospital of Majadahonda (Madrid) approved the project and the studies were conducted according to the principles of Helsinki's Declaration. All patients or their caregivers in cases of cognitive impairment gave written informed consent before enrolment.
Thrombus collection and sample preparation
Thrombi aspirated from the coronary artery through the thrombectomy device were collected in one or more segments, but total weight of the thrombi and their macroscopic appearance were similar between both groups under study. After extraction, thrombi were washed with saline solution and immediately fixed in 10% neutral buffered formalin for immunohistochemical analysis or directly frozen at -80ºC for proteomic analysis.
Previous to immunohistochemical analysis the thrombi were embedded in OCT (optimal cutting temperature compound).
For proteomic studies, protein extraction was performed using urea/detergent buffer (7 mol/L urea; 2mol/L thiourea; 2% CHAPS) as previously described (2, 3) . Protein concentration was measured with 2D-Quant Kit (GE Healthcare, Uppsala, Sweden). All processed samples were stored at -80ºC until used.
Immunohistochemistry
Immunohistochemical analysis was performed as previously described (2) . In brief, serial section (5 m thick) of OCT embedded thrombi were placed on poly-L-lysine coated slides and treated with of H 2 O 2, for inhibition of endogenous peroxidase activity, and with horse or goat serum to block non-specific bindings. Slides were incubated for 2h with antibodies against CD61 (platelets), CD3 (T-lymphocytes), CD105 and CD34 (undifferentiated cells), and with antibodies anti-monocyte/macrophage, antineutrophils and anti-fibrin(ogen) and detected with avidin-biotin immunoperoxidase technique. The chromogen used was 3.3'-diaminobenzidine.
Hematoxylin and eosin (H&E) staining was routinely performed in all thrombi as a first approach, previously to the immunohistochemical analysis, to identify sample morphology. The images were captured by Nikon Eclipse 80i microscope and digitized by Retiga 1300i Fast camera at 400x. Positive staining areas for each antigen were calculated from an average of 5-fields/sample with ImageJ 1.37v software. The values were given as a percentage of the total thrombus area (content (%) = [positive stained area/total thrombus area] x100).
Proteomic analysis
Analysis of differential protein expression patterns and protein identification was performed by a proteomic approach using two-dimensional electrophoresis and massspectrometry identification, as previously described (2, 3) . Two-dimensional gel electrophoresis (2-DE): For analytical and preparative gels, 100 g and 300 g of protein of the urea/chaps thrombi extracts were respectively loaded in 17-cm dry strips (pH 3-10 linear range, GE Healthcare, Uppsala, Sweden) and the proteins were separated by electrofocussing according to their isoelectric point (pI). Electrophoresis was performed Second dimension was resolved in 12% SDS-PAGE gels using an Ettan Daltssix System (GE HealthCare, Uppsala, Sweden). Gels were developed by fluorescent staining (Flamingo, BioRad). For each independent experiment, 2-DE for protein extracts from each group of patients were processed in parallel to guarantee a maximum of comparability. In 2-DE analyses, the proteomic profile of the analyzed groups was compared by using the PD-Quest 8.0 software (BioRad) that specifically analyzes the differences in protein patterns by using a single master that includes all the gels of each independent experiment (samples from all the groups included in the experiment). In this analysis, each spot in the gel is assigned a relative value that corresponds to the single spot volume compared to the volume of all spots in this gel in order to avoid potential differences due to technical variability, as previously described (2, 3) . Afterwards, this value is subjected to background extraction and the final intensity value is then normalized by the local regression model (LOESS) method of the software.
Mass spectrometry analysis: Proteins were identified after in-gel tryptic digestion and extraction of peptides from the gels pieces, as previously described (2, 3) where a mascot score higher than 56 and at least five matched peptides was accepted, as previously reported (4) . Identified proteins were then confirmed by peptide fragmentation working on the reflector mode (MS/MS).
Western Blot validation
Thrombus protein extracts (25 g of total protein) were resolved in 12% SDS-PAGE under reducing conditions and electrotransferred to nitrocellulose membranes in semidry conditions (TransBlot Turbo transfer system, BioRad). Detection was performed with a monoclonal antibody against peroxiredoxin-2 (1:2000 dilution, Abcam) and polyclonal antibodies against superoxide dismutase (1:1000 dilution, Calbiochem), glutathione peroxidase-2 (1:1000 dilution, Abcam) and catalase (1:1000 dilution, Abcam). After the addition of the secondary anti-mouse antibody (1:10000 dilution, Dako) chemiluminescence detection was performed with ChemiDoc XRS (BioRad). Band intensity quantification was performed using ImageLab v4.0 software (BioRad). Protein load was normalized using total protein fluorescent signal, as previously published (4).
Quantification of systemic protein and advanced oxidation protein products levels
Systemic peroxiredoxin-2 (PRX-2) and heat shock cognate 71kDa (HSC70) total concentrations were determined in serum by sandwich enzyme-linked immunosorbent assays using immobilized antibodies, as described by the providers (Cusabio). The detection limits of the assays were 11.8 ng/ml for PRX-2 and 7.8 pg/ml for HSC70. The intra-and inter-assay variabilities were <8% and <10% for both assays. Samples from CT (N=18) and IST (N=14) groups were analyzed including patients from phases I (N=8) and II (N=12). Haemolyzed samples had to be discarded because of the strong influence of haemolysis on oxidative stress-related measurements.
In silico bioinformatic analysis
The statistically significant neural network and canonical pathway in which the identified proteins were involved were generated through the use of IPA (Ingenuity System, www.ingenuity.com).
Functional analysis of a network: The functional analysis of a network was used to identify the biological functions and/or diseases that were most significant to the molecules in the network. The network molecules associated with biological functions and/or diseases in the Ingenuity Knowledge Base were considered for the analysis. Right-tailed Fisher's exact test was used to calculate a p-value determining the probability that each biological function and/or disease assigned to that network is due to chance alone.
Canonical pathway analysis: Canonical pathway analysis was used to identify the pathways from the IPA library that were most significant to the data set. The significance of the association between the data set and the canonical pathway was measured in 2 ways: 1) A ratio of the number of molecules from the data set that maps to the pathway divided by the total number of molecules that maps to the canonical pathway is displayed. 2) Fisher's exact test was used to calculate a p-value determining the probability that the association between the genes in the data set and the canonical pathway is explained by chance alone. Suppl. 
Statistical analysis

